ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

New Coalition To Lobby for Prevention

November 24, 1978

In Brief: More Than 1,600 Taking First Oncology Nurse Certification Exam; FCC Discussions Planned

April 4, 1986

NIH Grants: R29 Awards No Longer Accepted After June; NIH To Increase R01s.

December 5, 1997

Cancer Training Programs Fairing Fairley Well

December 1, 1989

Minnesota Study Aimed At Finding Final Answer On Hemoccult Screening

July 24, 1987

NCI Advisory Group, Other Cancer Meetings

July 25, 1986